Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data (Revised)

Published on November 12, 2021

Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.

Continue reading on website
Other news

Euroseas's (ESEA) to Report Q3 Earnings: What's in the Offing?

November 12, 2021
Higher revenues are likely to have boosted Euroseas's (ESEA) Q3 performance.

Here's the Secret to Reducing Employee Turnover and Cutting Costs

November 12, 2021
Hiring and nurturing the right fit for a position can have a multiplier effect on your business.